FDA Guidance for Expedited Programs For Serious Conditions

Article

FDA updates guidelines to expedite the development and review of new drugs.

FDA updates guidelines to expedite the development and review of new drugs.

The FDA just released its guidance for industry regarding expedited programs for serious conditions. There are four FDA programs intended to expedite the development and review of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition. They are: 1) fast track designation, 2) breakthrough therapy designation, 3) accelerated approval, and 4) priority review designation.

Fast Track Designation

Drug to treat a serious disease and fill an unmet medical need.

Key Points

  • Designation may be granted on the basis of preclinical or clinical data
  • Process designed to facilitate development and expedite review
  • Fast Track designated drugs are eligible for: More frequent interactions with FDA (meetings or written correspondence) during drug development Rolling review, whereby companies can submit completed sections of marketing applications for FDA review, rather than waiting until every section is complete

Breakthrough Therapy Designation

Drug intended to treat a serious or life-threatening disease in which there is currently a treatment available.

Click here to read the full article on Rare Disease Report.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.